182 related articles for article (PubMed ID: 36923304)
1. Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Eisner JR; Beebe KD; Mayhew GM; Shibata Y; Guo Y; Farhangfar C; Farhangfar F; Uronis JM; Mooney J; Milburn MV; Foureau D; White RL; Amin A; Milla ME
Cancer Res Commun; 2022 Aug; 2(8):894-903. PubMed ID: 36923304
[TBL] [Abstract][Full Text] [Related]
2. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
3. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
[TBL] [Abstract][Full Text] [Related]
4. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
6. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
8. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
9. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
Lam ET; Wong MK; Agarwal N; Redman BG; Logan T; Gao D; Flaig TW; Lewis K; Poust J; Monk P; Jarkowski A; Sendilnathan A; Bolden M; Kuzel TM; Olencki T
J Immunother; 2014 Sep; 37(7):360-5. PubMed ID: 25075565
[TBL] [Abstract][Full Text] [Related]
11. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.
Hannan R; Mohamad O; Diaz de Leon A; Manna S; Pop LM; Zhang Z; Mannala S; Christie A; Christley S; Monson N; Ishihara D; Hsu EJ; Ahn C; Kapur P; Chen M; Arriaga Y; Courtney K; Cantarel B; Wakeland EK; Fu YX; Pedrosa I; Cowell L; Wang T; Margulis V; Choy H; Timmerman RD; Brugarolas J
Clin Cancer Res; 2021 Dec; 27(24):6716-6725. PubMed ID: 34551906
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
14. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
18. Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.
Mehta K; Appleman L; Wang H; Tarhini AA; Parikh RA
PLoS One; 2016; 11(1):e0147153. PubMed ID: 26799322
[TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
20. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
